• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Alcami

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    Emergent BioSolutions

    PCI Pharma Services

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Improving Pharma R&D Efficiency: The need to transform clinical trials

    Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t

    Improving Pharma R&D Efficiency: The need to transform clinical trials
    Related CONTENT
    • Decentralized Clinical Trials: The 101 on Digital Health Technologies (DHTs)
    • Revolo Biotherapeutics, CordenPharma Enter Master Service Agreement
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    • Metrics Names Stephanie Emory Associate Director of Pharma Development
    ICON plc10.10.18
    Declining research and development (R&D) efficiency is one of the biggest challenges pharmaceutical manufacturers face today. Total sponsor cost per new drug approved in the U.S. jumped 145% in just 15 years to more than $2.5 billion in 2014, according to the Tufts Center for Drug Development. At the same time, just seven percent of first-in-human drugs gained FDA approval.1
    The costs and risks of drug development have never been higher in both financial and human terms.

    These inefficiencies largely result from an outdated clinical trial model. Nearly $1.5 billion per approved new drug is attributed to clinical development, the majority of which is for clinical studies. The traditional approach of three discrete, fixed trial phases designed for testing mass-market drugs often is not viable in today’s increasingly competitive, value-based therapeutic markets. It lacks the flexibility, analytic power and speed required to develop complex new therapies targeting smaller and often heterogeneous patient populations.2

    With development cycles becoming too long, trial complexity increasing, and greater scrutiny of the economic value of new treatments, pharma R&D business models are under significant pressures to improve R&D efficiency.

    In an industry survey of pharmaceutical executives and professionals by ICON and Pharma Intelligence the challenges most frequently cited are:
    • Patient enrollment—56% of survey respondents;
    • Site start-up—43% of respondents; and
    • Regulatory approval delays and changes—43% of respondents.
    These operational issues reflect the difficulty of designing studies that address critical patient and investigator needs, as well as evolving regulations.

    Elevating efficiency & enhancing trial savings
    Patient identification and recruitment and risk-based approaches to study monitoring are expected to have the most impact in transforming the efficiency, speed, and productivity of clinical development.

    In our survey, the top five key areas identified by industry experts as having the most potential for generating savings and improving trial efficiency were:
    • Improving protocol development —38% of respondents;
    • Study start-up activities —37% of respondents;
    • Patient recruitment and retention —37% of respondents;
    • Vendor selection and management —32% of respondents; and
    • Study monitoring —25% of respondents.
    Declining pharmaceutical R&D efficiency and the resulting deterioration in return on investment is largely driven by lengthening development cycles. These, in turn, typically involve increasing trial complexity and regulatory approval delays. These complexities and delays are symptomatic of deep structural changes in therapeutic markets that conventional clinical trials are simply not designed to address.

    Market changes
    Some of these market changes are addressed below.

    Smaller Targets. The traditional three-stage randomized clinical trial structure was built to study drugs intended to treat large populations. The numbers involved made it relatively easy to recruit for very large trials, while mass market potential made it economically feasible to conduct them. Today’s markets are different. Driven by scientific advances in areas including biochemistry, genomics and biomarkers, the market for new therapies has moved toward targeted therapies and orphan indications, with big gains in approvals for neoplastic therapies and declines in cardiovascular and broad spectrum anti-infectives since 1980.3 

    The smaller potential markets mean the R&D enterprise—and clinical trial designs and procedures—must be tightly focused on patient needs, relevant clinical and research expertise, and maximizing efficiency in demonstrating safety and efficacy.

    Personalized Medicine. Taking the smaller target trend to its logical conclusion, the market for personalized medicine is growing exponentially. New product offerings target specific biomarkers, such as biologic chemotherapy agents, or even individual patients, such as CAR-T immunotherapy. Similarly, therapies that combine mobile sensors and devices with drugs and delivery devices, such as an artificial pancreas or apps assessing the daily effects of Parkinson’s or other mobility-restricting conditions, require evidence of real-world efficacy and safety that cannot be generated in a controlled environment.

    Value-Based Care. Rising healthcare costs as a percentage of GDP is driving greater scrutiny of the economic value of new treatments by government and private payers. In addition to efficacy and safety, clinical trials increasingly must demonstrate a meaningful impact on patients’ lives. This is particularly true for high-cost therapies targeting smaller patient groups, many of which struggle to be covered by national health systems and private insurers. Screening patients to identify potentially better responders and linking payments to individual patient outcomes are among the measures payers are negotiating with sponsors to ensure they are getting value for the money they spend.

    Approaches to adopt
    Adaptive Clinical Trials. Broader use of trials that modify study protocols in predetermined ways based on interim patient data have the potential to eliminate many unanticipated risks that undermine efficacious drugs and unnecessarily extend development timelines.

    For example, adaptive approaches often can deliver in a single two-year period combined Phase II/III trial information that otherwise might require three or more consecutive conventional trials over three or more years. These seamless trials reduce the total sample size needed by combining data from patients studied in both phases of the trial. We estimate that optimal use of adaptive trials across a portfolio, which is encouraged by regulatory agencies in Europe and the US, could reduce trial costs, by 25%.

    Automated Data Collection and Analytics. Basing trial inclusion criteria on actual patient data, automatically identified from electronic medical records (EMR), reduces the risk of extra cost and delays when unrealistic recruitment protocols need to be revised. Accessing EMR data can also cut recruitment costs, while automated site support and monitoring greatly reduce start-up and site management costs while ensuring that data are properly collected and validated. Remote data links enable data collection directly from patients at home, reducing the number of costly site visits required for a trial. EMR data allow automated post-market surveillance in Phase IV trials.

    Real World Data. The traditional three-stage randomized control trial (RCT) model is not designed to collect information that meets emerging market needs. In some cases, the populations involved are too small to conduct randomized trials. While RCTs are likely to remain the gold standard for validating the safety and efficacy of new compounds for initial registration, innovative trials using real-world data are likely to play an increasing role in defining new, patient-centered endpoints and expanding and refining indications.

    Collecting real world data (RWD) to expand label indications, or to truly personalize therapies, cannot be done in a strictly controlled trial structure. Demonstrating value also requires collecting real-world clinical information, as well as non-clinical data on costs.

    Patient Centricity. Improving patients’ lives is the ultimate goal of drug development. It means everything from defining outcomes that make the most difference in patient’s lives, to offering trials to patients identified through EMRs in their physicians’ office, to minimizing control arms using advanced statistical methods and providing study results as soon as they are available.

    Patients want to have more input into research and treatment of their condition and its impact on their lives. This can benefit clinical research in many ways. Focused patient advocacy groups can help define new therapeutic targets, plan and recruit patients to trials, and demonstrate the value that new therapies bring to their lives.

    Making clinical trials available as a treatment option when patients present for primary care, secondary care, and at the consultant level could greatly expand participation. Organizations such as PMG Research address this gap by partnering with physician networks to provide sophisticated trial support in community settings.

    The impact of digital disruption
    Emerging technology capabilities are expected to play a vital role in transforming clinical trials—including leveraging big data and predictive analytics—which can enable the efficient identification of promising study subjects and sites, as well as risk-based monitoring of trial performance in real time. Integrating study and electronic health records (EHR) may increase data collection reach and efficiency, and help better integrate trials into clinical practice.

    Patient-focused technologies, including mobile sensors, smartphone apps and telemedicine, are seen as ways to collect richer patient data, develop new endpoints and help design novel kinds of trials that may better demonstrate real-world clinical and functional value.

    Big Data. The world’s capacity for producing data is expanding exponentially, and that data, from medical and non-medical sources, has the potential to greatly increase the efficiency of clinical R&D.

    However, establishing and structuring data sourced from diverse systems is required, and this can be technically daunting. Outcomes based on such data also must be modelled and validated, and this, too, requires significant expertise.

    Wearables & Mobile Devices. Within trials, mobile apps and sensors can measure key symptoms and signs, such as tremor, blood pressure, blood sugar or activity level, while diagnostic apps, reminders and telemedicine can help keep patients engaged and on protocol. Sensors also may support development and measurement of new endpoints that are more relevant to patient needs.
    As with big data, though, new outcome measures and endpoints using mobile devices must be rigorously validated, as must the use of any mobile device supplied by patients to support any apps and sensors used in a clinical trial.

    Statistical Analysis & Artificial Intelligence (AI). AI is another area evolving alongside the data explosion—AI-enabled measures include data integration, data management and interpretation. These can improve trial performance at every level, from enabling risk-based trial monitoring to modelling investment return at the portfolio level.

    Powerful statistical approaches, including Bayesian statistics for guiding trial design based on accumulating evidence and MCP-Mod for dose-finding, can greatly increase the efficiency of trials, making smaller trials possible by achieving adequate statistical power with fewer subjects. Regulators increasingly are embracing these advanced features, as evidenced by the FDA’s designation of MCP-Mod as ‘fit for purpose’ to improve dose finding efficiency, and are being incorporated into powerful trial design software packages such as ADDPLAN.

    However, applying AI and advanced statistical methods requires effort, often including extensive process modelling, and a high degree of specialized skill to achieve results useful for development and acceptable to regulators.

    While the technical challenges of applying these new technologies to clinical trials are significant, their value already has been confirmed in many studies, saving millions in development costs. They make possible innovations that are fundamental for transforming clinical trials, such as seamlessly combining phase I and II of clinical trials, developing novel patient-centered endpoints, and collecting and analyzing real world data.

    A holistic, integrated approach to transformation
    The cost pressures on drug development are driving the search for savings. Whilst large-scale operational efficiencies are being instituted in many pharmaceutical organizations, efforts need to be integrated if they are to be effective.

    There is a growing understanding that improving R&D efficiency and return on investment will take more than gradually adopting a number of new technologies. It will require a holistic approach to transforming trials, rethinking and redesigning the trial product itself and the enterprise that supports trials from the ground up.

    Transforming clinical trials is essential. A comprehensive rethinking of the entire clinical trials process that uses new approaches coupled with existing, tested technologies to substantially reduce the risk and cost of clinical drug development, is the way of the future. 

    References
    1. DiMasi et al. Cost of Developing a New Drug. Tufts Center for the Study of Drug Development, 2014.
    2. Jones DS et al. The Burden of Disease and the Changing Task of Medicine.
    3. N Engl J Med 2012; 366:2333-2338 June 21 2012, DOI: 10.1056/NEJMp1113569.
    4. Tufts Center for the Study of Drug Development – Outlook 2016.
    Related Searches
    • Phase I
    • data management
    • it
    • biomarkers
    Suggested For You
    Decentralized Clinical Trials: The 101 on Digital Health Technologies (DHTs) Decentralized Clinical Trials: The 101 on Digital Health Technologies (DHTs)
    Revolo Biotherapeutics, CordenPharma Enter Master Service Agreement Revolo Biotherapeutics, CordenPharma Enter Master Service Agreement
    Kintor, Visum Enter COVID-19 Manufacturing Partnership Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Catalent Adds Cryogenic Capabilities at Philadelphia Facility Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    Metrics Names Stephanie Emory Associate Director of Pharma Development Metrics Names Stephanie Emory Associate Director of Pharma Development
    BioVersys Gets EIB Funds to Address Antimicrobial Resistance BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Vetter Development Service Vetter Development Service
    AJILITY: Intelligent Drug Product Manufacturing AJILITY: Intelligent Drug Product Manufacturing
    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans Agilex Biolabs Acquires TetraQ for APAC Expansion Plans
    Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    Moleculin Selects IQVIA Biotech to Advance COVID Treatment Moleculin Selects IQVIA Biotech to Advance COVID Treatment
    Cryoport Acquires Critical Transport Solutions Australia Cryoport Acquires Critical Transport Solutions Australia
    CordenPharma Enters Alliance with Nanos of South Korea CordenPharma Enters Alliance with Nanos of South Korea
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21


    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20


    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19


    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18

    • R&D
      A Blueprint to Unify Clinical Operations

      A Blueprint to Unify Clinical Operations

      Fast-growing clinical research organization speeds study execution and improves quality
      Jim Reilly, VP of Clinical Market Strategy, Veeva Systems 05.08.18


    • R&D
      Newsmakers: Charles River

      Newsmakers: Charles River

      Charles River Expands
      Kristin Brooks, Managing Editor 05.07.18

    • R&D
      CRO Consolidations: A Boon for Pharma?

      CRO Consolidations: A Boon for Pharma?

      In the contract research space there is a movement towards consolidation in order to expand capabilities and reach to service
      Craig Morgan, Head of Marketing, goBalto 11.07.17

    • R&D
      Streamlining Operations:  Sponsor-CRO Partnership Trends

      Streamlining Operations: Sponsor-CRO Partnership Trends

      Clinical teams have the opportunity to shed decades-old siloed operating model.
      Jim Reilly, Veeva Systems 09.06.17

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Carton Service Launches Custom Green Packaging Solutions
    • Valneva Focuses On Bilateral Discussions To Supply COVID-19 Vax
    • Thermo Fisher Acquires PPD For $17.4B
    • PRA Health Sciences Expands Pharmacovigilance Services
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    PPG Maintains EcoVadis Gold Rating
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Johnson & Johnson Reports Sales Increase in First Quarter of 2021
    THG Launches Recycling Program in UK
    Knoll Printing & Packaging Commits to a Healthy Ocean and Planet
    Happi

    Latest Breaking News From Happi

    L’Oréal Successfully Defends Itself In Patent Infringement Lawsuit
    TFF Names 2021 Honorees for Lifetime Achievement Perfumer and Hall of Fame
    Ashland Donates $20,000 To Help Plant Trees
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Ashland commits to forest restoration
    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login